•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Levi & Korsinsky has notified investors that it has commenced an investigation into Qiagen N.V. (NYSE: QGEN) regarding potential violations of federal securities laws.
During Qiagen’s previous earnings call on February 5, 2026, CEO Thierry Bernard expressed confidence in the company’s outlook for QuantiFERON, stating: “You will see QuantiFERON picking up in Q2 accelerating to achieve between 6% and 7% growth” in 2026. He also said Qiagen’s projections remained “perfectly aligned with the target that we gave during our Capital Market Day in June 2024.”
On April 28, 2026, Qiagen walked back those claims. CFO Roland Sackers disclosed updated guidance, saying sales were projected to “continue at a largely unchanged level from the second quarter of 2025,” and that investors would need to wait for QuantiFERON to “return to a more normalized growth rate in 2027.”
Levi & Korsinsky said it is investigating potential securities-law violations and encouraged investors who suffered losses on Qiagen N.V. securities to explore a potential recovery under federal securities laws.
Joseph E. Levi, Esq. and Ed Korsinsky of Levi & Korsinsky, LLP can be reached at:
Premium gym chains are entering a “golden era” that is ending or already in decline, as rising operating costs collide with shifting consumer preferences toward more flexible, community-based ways to exercise. Long-term memberships are shrinking, margins are pressured by higher rents and facility expenses, and competition from smaller, more personalized…
